Celltrion to acquire additional $72 mn in treasury shares

From November 22, the company's 583,431 shares will be repurchased on the market, bringing the total to $308 mn

Celltrion to acquire additional  mn in treasury shares
Dae-Kyu Ahn 1
2024-11-21 16:08:27 powerzanic@hankyung.com
Bio & Pharma

South Korea's Celltrion Inc. announced on Thursday that it decided to repurchase additional treasury shares worth 100 billion won ($71.6 million).

From November 22, Celltrion plans to acquire 583,431 treasury shares through on-market purchases.

The company stated that this additional buyback is part of a shareholder-friendly policy to prioritize and enhance shareholder value.

The decision was made in response to the company's judgment that its corporate valuation has slowed, despite achieving record-breaking third-quarter sales and ongoing growth of its flagship products in global markets, along with approvals for new products.

Previously, Celltrion projected that its revenue for this year would reach a record high of 3.5 trillion won ($2.5 billion).

This marks the fifth share buyback by Celltrion this year, bringing the cumulative total for 2024 to 2,394,031 shares worth 430 billion won ($307.7 million).

Celltrion has consistently pursued shareholder value enhancement policies, including repurchasing 1,239 billion won ($886.5 million) worth of treasury shares last year.

This year, the company has also combined share buybacks with the cancellation of 700 billion won ($500.9 million) worth of treasury shares.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com

Celltrion acquires Swiss pharmaceutical distributor iQone

Celltrion acquires Swiss pharmaceutical distributor iQone

South Korea's Celltrion Inc. said on Friday that it completed its acquisition of iQone Healthcare Switzerland, a Swiss pharmaceutical distributor, to begin direct sales in Switzerland.The acquisition, valued at approximately 30 billion won ($21 million), was conducted through Celltrion’s

Celltrion releases Steqeyma in Europe

Celltrion releases Steqeyma in Europe

South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.The company introduced Steqeyma in Germany on November 1, promoting the product’s competitive edge to local medical professionals, including

Celltrion's Zymfentra gets 90% distribution channel in US

Celltrion's Zymfentra gets 90% distribution channel in US

South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), got 90% of the distribution channel in the US. The company said on Tuesday that it succeeded in listing Zymfentra in all six public and priva

Celltrion to establish CDMO subsidiary

Celltrion to establish CDMO subsidiary

Celltrion Inc., South Korea’s largest biosimilar maker, said on Friday it plans to establish a contract development and manufacturing organization (CDMO) as a wholly-owned subsidiary by the end of this year."The key focus of this plan is to secure a competitive edge over existing CDMO co

Celltrion's anti cancer drugs hold 90% market share in C.America

Celltrion's anti cancer drugs hold 90% market share in C.America

South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries.The company’s biosimilar drug Truxima, a version of Roche’s blood cancer treatment Rituxan, has held over 90% market share in Costa Ri